Cargando…

The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes

Objective. Sclerostin is a Wnt inhibitor produced specifically by osteocytes. However, it is not currently clear whether renal dysfunction has an effect on circulating sclerostin level in patients with type 2 diabetes. The aim of the study was to evaluate this relationship. Design and Patients. We c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Se Hwa, Yoon, Soo Young, Lim, Sung-Kil, Rhee, Yumie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099222/ https://www.ncbi.nlm.nih.gov/pubmed/25053944 http://dx.doi.org/10.1155/2014/715908

Ejemplares similares

Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
por: Kim, Wonjin, et al.
Publicado: (2015)

The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction
por: Mihaljević, Olgica, et al.
Publicado: (2020)

Circulating levels of sclerostin are associated with cardiovascular mortality
por: Novo-Rodríguez, Cristina, et al.
Publicado: (2018)

Effect of adrenocorticotropic hormone infusion on circulating sclerostin levels
por: Zaheer, Sarah, et al.
Publicado: (2021)

Regulation of Circulating Sclerostin Levels by Sex Steroids in Women and in Men
por: Mödder, Ulrike IL, et al.
Publicado: (2011)

Circulating bioactive sclerostin levels in an Austrian population-based cohort
por: Kerschan-Schindl, Katharina, et al.
Publicado: (2021)

Atherosclerotic Disease in Type 2 Diabetes Is Associated With an Increase in Sclerostin Levels
por: Morales-Santana, Sonia, et al.
Publicado: (2013)

Circulating Levels of Sclerostin Predict Glycemic Improvement after Sleeve Gastrectomy
por: Carbone, Federico, et al.
Publicado: (2021)

Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men
por: Mödder, Ulrike I, et al.
Publicado: (2011)

Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD
por: Behets, Geert J., et al.
Publicado: (2017)

Expression and Regulation of Osteoprotegerin in Adipose Tissue
por: An, Juan-Ji, et al.
Publicado: (2007)

Serum sclerostin levels in renal cell carcinoma patients with bone metastases
por: Wibmer, C., et al.
Publicado: (2016)

Effects of Single Vitamin D(3) Injection (200,000 Units) on Serum Fibroblast Growth Factor 23 and Sclerostin Levels in Subjects with Vitamin D Deficiency
por: Zhang, Dongdong, et al.
Publicado: (2017)

Cardiac Dysfunction in Association with Increased Inflammatory Markers in Primary Aldosteronism
por: Lim, Jung Soo, et al.
Publicado: (2016)

Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease
por: Kim, Gyuri, et al.
Publicado: (2017)

Sclerostin
por: Silverman, Stuart L.
Publicado: (2010)

Decreased Serum Level of Sclerostin in Older Adults with Sarcopenia
por: Ahn, Seong Hee, et al.
Publicado: (2022)

Parathyroid Hormone Regulates Circulating Levels of Sclerostin and FGF23 in a Primary Hyperparathyroidism Model
por: Nagata, Yuki, et al.
Publicado: (2022)

Circulating Sclerostin Levels Are Positively Related to Coronary Artery Disease Severity and Related Risk Factors
por: Frysz, Monika, et al.
Publicado: (2021)

Serum γ-Glutamyl Transferase Is Inversely Associated with Bone Mineral Density Independently of Alcohol Consumption
por: Choi, Han Seok, et al.
Publicado: (2016)

Sclerostin, Osteocytes, and Wnt Signaling in Pediatric Renal Osteodystrophy
por: Laster, Marciana, et al.
Publicado: (2023)

Corrigendum: IRB Approval Number Correction. Cardiac Dysfunction in Association with Increased Inflammatory Markers in Primary Aldosteronism
por: Lim, Jung Soo, et al.
Publicado: (2020)

Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling
por: van Dinther, Maarten, et al.
Publicado: (2013)

Serum sclerostin levels in osteoporotic fracture patients
por: Gorter, Erwin A., et al.
Publicado: (2022)

Modifications of T-Scores by Quantitative Ultrasonography for the Diagnosis of Osteoporosis in Koreans
por: Rhee, Yumie, et al.
Publicado: (2009)

Serum 1,5-Anhydroglucitol Concentrations Are a Reliable Index of Glycemic Control in Type 2 Diabetes With Mild or Moderate Renal Dysfunction
por: Kim, Won Jun, et al.
Publicado: (2012)

Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus
por: Ross, Ryan D., et al.
Publicado: (2020)

Mendelian Randomization Analysis Reveals a Causal Influence of Circulating Sclerostin Levels on Bone Mineral Density and Fractures
por: Zheng, Jie, et al.
Publicado: (2019)

Serum sclerostin level is positively associated with endothelial dysfunction measured by digital thermal monitoring in patients with type 2 diabetes: A prospective cross-sectional study
por: Hsu, Bang-Gee, et al.
Publicado: (2023)

Site-Specific Difference of Bone Geometry Indices in Hypoparathyroid Patients
por: Park, Hye-Sun, et al.
Publicado: (2017)

The effect of single extremity-vibration on the serum sclerostin level
por: Cakar, Halil Ibrahim, et al.
Publicado: (2015)

Circulating Sclerostin and Irisin Are Related and Interact with Gender to Influence Adiposity in Adults with Prediabetes
por: Klangjareonchai, Theerawut, et al.
Publicado: (2014)

Circulating sclerostin is not suppressed following a single bout of exercise in young men
por: Guerriere, Katelyn I., et al.
Publicado: (2018)

Low sclerostin levels after long-term remission of acromegaly
por: Claessen, Kim M. J. A., et al.
Publicado: (2021)

Effect of Zoledronic Acid on Acro-Osteolysis and Osteoporosis in a Patient with Hajdu-Cheney Syndrome
por: Hwang, Sena, et al.
Publicado: (2011)

Sclerostin and Vascular Pathophysiology
por: Catalano, Antonino, et al.
Publicado: (2020)

Sclerostin and Cardiovascular Disease
por: Tobias, Jonathan H.
Publicado: (2023)

In Vitro & In Vivo Effect of Parathyroid Hormone Analogue (1-14) Containing α-amino-iso-butyric Acid Residue (Aib)(1,3)
por: Rhee, Yumie, et al.
Publicado: (2006)

Circulating CTRP1 Levels in Type 2 Diabetes and Their Association with FGF21
por: Han, Sora, et al.
Publicado: (2016)

Serum Sclerostin, Body Composition, and Sarcopenia in Hemodialysis Patients with Diabetes
por: Medeiros, Maria Carolina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4hjvt9ouu3kh1l000harkdopt3